Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies.
Distribution of the photosensitizer Foscan (meta-tetrahydroxyphenylchlorin, mTHPC), after i.v. or i.p. injection, was investigated in Wag/Rij rats bearing i.p. tumours. These results were compared with the efficacy of mTHPC-mediated photodynamic therapy for illumination intervals of 4 hr to 3 days. For the distribution experiments a single tumour (CC53I colon carcinoma) was implanted intra-abdominally in a fat pad, or a cell suspension (1 x 10(6) CC531 cells) was injected into the peritoneal cavity, which results in a dissemination of tumour nodules on the peritoneum. 14C-mTHPC was not selectively taken up in the single-tumour model after i.v. or i.p. injection, but higher concentrations were achieved for i.p. administration. For this tumour model the concentration ratios between tumour and normal tissue never exceeded a value of 3. In the disseminated-tumour model, an uptake of up to 40% of the injected dose was found per gram tumour at 4 hr after an i.p. injection and this resulted in very high (> 14) concentration ratios of tumour to normal tissues. Low uptake was found after the i.v. injection route (1% of the injected dose per gram tumour) with lower tumour/normal tissue ratios (<8). The efficacy of i.p. photodynamic therapy (IPPDT) was evaluated using the single-tumour model only. The lower abdomen was illuminated at 4 hr to 3 days after mTHPC, and tumour size was repeatedly measured via a small laparoscopy. Significant delay in tumour regrowth was achieved for 6 J x cm-2 at 1 day after i.v., or at 4 hr after i.p. mTHPC (p values 0.019 and 0.045 respectively). Response to PDT, of tumours implanted in the fat pad, was not greater for i.p. administration of the photosensitizer and there was a poor correlation between times of maximum drug uptake in tumours and optimal illumination times for PDT efficacy.
Veenhuizen
R B
RB
Experimental Therapy Division, Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands.
Ruevekamp
M C
MC
Oppelaar
H
H
Helmerhorst
T J
TJ
Kenemans
P
P
Stewart
F A
FA
D000273:Adipose Tissue; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008652:Mesoporphyrins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D051381:Rats; D014018:Tissue Distribution
D008652:Mesoporphyrins; D017319:Photosensitizing Agents; C072269:temoporfin